Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Benatar

Showing results (221-230 of 242) with videos related to

Pageof 25
Sort By:
Neurological Research and Practice|August 20, 2025
Identification of a presymptomatic and early disease signature for amyotrophic lateral sclerosis (ALS): protocol of the premodiALS studyLaura Tzeplaeff, Ana Galhoz, Clara Meijs, et al.
Nature Neuroscience|December 21, 2019
Publisher Correction: Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock proteinSali M K Farhan, Daniel P Howrigan, Liam E Abbott, et al.
The Lancet. Neurology|May 23, 2024
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichael Benatar, Thomas Hansen, Dror Rom, et al.
Nature|March 5, 2013
Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALSHong Joo Kim, Nam Chul Kim, Yong-Dong Wang, et al.
BMJ Open|September 19, 2020
Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North AmericaJoshua D Green, Richard J Barohn, Emanuela Bartoccion, et al.
Medrxiv : the Preprint Server for Health Sciences|September 5, 2025
Redefining ALS: Large-scale proteomic profiling reveals a prolonged pre-diagnostic phase with immune, muscular, metabolic, and brain involvementJan Homann, Roxanna Korologou-Linden, Vivian Viallon, et al.
Research Square|September 15, 2025
Redefining ALS: Large-scale proteomic profiling reveals a prolonged pre-diagnostic phase with immune, muscular, metabolic, and brain involvementJan Homann, Roxanna Korologou-Linden, Vivian Viallon, et al.
Neurology|July 3, 2020
Minimal manifestation status and prednisone withdrawal in the MGTX trialIkjae Lee, Hui-Chien Kuo, Inmaculada B Aban, et al.
The Lancet. Neurology|January 30, 2019
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trialGil I Wolfe, Henry J Kaminski, Inmaculada B Aban, et al.
The New England Journal of Medicine|August 11, 2016
Randomized Trial of Thymectomy in Myasthenia GravisGil I Wolfe, Henry J Kaminski, Inmaculada B Aban, et al.
Pageof 25

Showing results (221-230 of 242) with videos related to

Sort By:
Pageof 25
Neurological Research and Practice|August 20, 2025
Identification of a presymptomatic and early disease signature for amyotrophic lateral sclerosis (ALS): protocol of the premodiALS studyLaura Tzeplaeff, Ana Galhoz, Clara Meijs, et al.
Nature Neuroscience|December 21, 2019
Publisher Correction: Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock proteinSali M K Farhan, Daniel P Howrigan, Liam E Abbott, et al.
The Lancet. Neurology|May 23, 2024
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichael Benatar, Thomas Hansen, Dror Rom, et al.
Nature|March 5, 2013
Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALSHong Joo Kim, Nam Chul Kim, Yong-Dong Wang, et al.
BMJ Open|September 19, 2020
Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North AmericaJoshua D Green, Richard J Barohn, Emanuela Bartoccion, et al.
Medrxiv : the Preprint Server for Health Sciences|September 5, 2025
Redefining ALS: Large-scale proteomic profiling reveals a prolonged pre-diagnostic phase with immune, muscular, metabolic, and brain involvementJan Homann, Roxanna Korologou-Linden, Vivian Viallon, et al.
Research Square|September 15, 2025
Redefining ALS: Large-scale proteomic profiling reveals a prolonged pre-diagnostic phase with immune, muscular, metabolic, and brain involvementJan Homann, Roxanna Korologou-Linden, Vivian Viallon, et al.
Neurology|July 3, 2020
Minimal manifestation status and prednisone withdrawal in the MGTX trialIkjae Lee, Hui-Chien Kuo, Inmaculada B Aban, et al.
The Lancet. Neurology|January 30, 2019
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trialGil I Wolfe, Henry J Kaminski, Inmaculada B Aban, et al.
The New England Journal of Medicine|August 11, 2016
Randomized Trial of Thymectomy in Myasthenia GravisGil I Wolfe, Henry J Kaminski, Inmaculada B Aban, et al.
Pageof 25